Psycheceutical Listed as 1 of 7 Psychedelic Stocks to Watch
PRESS ROOM
PSYCHECEUTICAL IN THE NEWS
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption
Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents
PODCASTS
PRESS RELEASES
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD
Read More Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)
Read More Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics
Read More Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology.
Read More Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments...
Read More Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board.
Read More Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor.
Read More Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor
Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.
Read More Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis
Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31…
Read More 